RxDoctor Payments Data

Pamela Boling, NP

Nurse Practitioner · Fort Wayne, INNPI 1750658399

Payments from drug & device makers

$2,709in general payments, 2019–2025

Across 157 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$441
  • Novo Nordisk$328
  • AstraZeneca$244
  • Lilly USA, LLC$235
  • Axsome Therapeutics, Inc.$212
  • Amgen$190
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,709 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$13,082
Medicare patients
67
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$33,150
OzempicSemaglutide25$26,602
FarxigaDapagliflozin Propanediol12$19,694
EliquisApixaban17$18,017
JardianceEmpagliflozin15$16,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,663
XareltoRivaroxaban11$8,565
SynthroidLevothyroxine Sodium20$1,254
Albuterol Sulfate HfaAlbuterol Sulfate39$1,190
Levothyroxine Sodium121$1,159
Atorvastatin Calcium126$1,050
Duloxetine Hcl16$782
Omeprazole56$751
Bupropion XlBupropion Hcl28$731
Venlafaxine Hcl ErVenlafaxine Hcl16$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$235$33,15029 claims
Novo NordiskOzempic$328$26,60225 claims
AstraZenecaFarxiga$244$19,69412 claims
PfizerEliquis$48$18,01717 claims
Boehringer IngelheimJardiance$14$16,60615 claims
GSKTrelegy Ellipta$42$13,66313 claims
AbbVieSynthroid$441$1,25420 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$1,159121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →